Abstract
Biomarkers can be used to aid the diagnosis of a disease (particularly early detection of occult tumours), to aid in the staging of disease, to predict outcome of disease, to act as a surrogate for clinical progression and to monitor responses to treatment. It is therefore important when referring to biomarkers to state exactly which of these indications is being sought. There is a real clinical need for biomarkers in all these stages, especially where patient stratification prior to treatment can considerably improve the outcome of clinical trials. Cancer, being a heterogeneous disease, is unlikely to respond to any one specific treatment and biomarkers that could tell us if the patient and their cancer was resistant to certain drugs would be very useful and, indeed, these are being sought. In an analogous way these are even more necessary with regards to vaccines, which would benefit greatly from patient stratification and early prediction of disease response [1].
Keywords: Biomarkers, cancer vaccines, cytokine profiles
Current Cancer Therapy Reviews
Title: Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines
Volume: 4 Issue: 2
Author(s): Angus G. Dalgleish
Affiliation:
Keywords: Biomarkers, cancer vaccines, cytokine profiles
Abstract: Biomarkers can be used to aid the diagnosis of a disease (particularly early detection of occult tumours), to aid in the staging of disease, to predict outcome of disease, to act as a surrogate for clinical progression and to monitor responses to treatment. It is therefore important when referring to biomarkers to state exactly which of these indications is being sought. There is a real clinical need for biomarkers in all these stages, especially where patient stratification prior to treatment can considerably improve the outcome of clinical trials. Cancer, being a heterogeneous disease, is unlikely to respond to any one specific treatment and biomarkers that could tell us if the patient and their cancer was resistant to certain drugs would be very useful and, indeed, these are being sought. In an analogous way these are even more necessary with regards to vaccines, which would benefit greatly from patient stratification and early prediction of disease response [1].
Export Options
About this article
Cite this article as:
Dalgleish G. Angus, Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310098
DOI https://dx.doi.org/10.2174/157339408784310098 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry A Comprehensive Review on Pharmacology and Toxicology of Bioactive Compounds of <i>Lagerstroemia Speciosa(L.</i>) Pers.
Current Traditional Medicine Cytotoxic and Chemopreventive Effects of Gemin D Against Different Mutagens Using In Vitro and In Vivo Assays
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic: A Dawn of New Era of Signal Transduction in Radiation Oncology (Guest Editor: Yuzuru Niibe)]
Current Signal Transduction Therapy What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation
Medicinal Chemistry The Macrophage Stimulating Protein/Ron Pathway as a Potential Therapeutic Target to Impede Multiple Mechanisms Involved in Breast Cancer Progression
Current Drug Targets Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Radiolabelling of Ascorbic Acid: A New Clue to Clarify its Action as an Anticancer Agent?
Current Radiopharmaceuticals Synthesis of New N1Arylpiperazine Substituted Xanthine Derivatives and Evaluation of their Antioxidant and Cytotoxic Effects
Anti-Cancer Agents in Medicinal Chemistry The Effects of Curcumin on Immune Responses
Current Bioactive Compounds Quantization of Angiogenesis and Image Analysis
Current Angiogenesis (Discontinued) Medicinal Chemistry of Probimane and MST-16: Comparison of Anticancer Effects Between Bisdioxopiperazines
Medicinal Chemistry Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Medullary Thyroid Cancer: New Targeted Molecular Therapies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Review on Epigenetic Effects of Environmental Factors Causing and Inhibiting Cancer
Current Molecular Medicine New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Tumour Hypoxia and Technetium Tracers: In Vivo Studies
Current Radiopharmaceuticals